FDA OKs Vraylar for Depression; Schizophrenia Fingerprint? Fanapt Works in Bipolar

The FDA has approved AbbVie’s cariprazine (Vraylar) as an adjunctive treatment for major depressive disorder, the company announced.

Telehealth pharmacy Truepill allegedly dispensed thousands of unlawful prescriptions for attention deficit-hyperactivity disorder (ADHD) stimulants like dextroamphetamine/amphetamine (Adderall), according to the Drug Enforcement Administration.

46%: that’s the proportion of U.S. teens who said they’ve experienced cyberbullying, according to a Pew Research Center survey.

The antibiotic linezolid did not significantly increase the risk for serotonin syndrome in people on antidepressants, a cohort study of older adults found. (JAMA Network Open)

A smartphone-based self-management intervention wasn’t much help for staving off relapse in people with bipolar disorder, though a hint of benefit was seen in low-risk patients. (JAMA Psychiatry)

Can a fingerprint predict schizophrenia? (Schizophrenia Bulletin)

Iloperidone tablets (Fanapt) significantly improved core symptoms of mania in adults with acute manic and mixed episodes associated with bipolar I disorder, according to phase III results released by Vanda Pharmaceuticals. The drug is already FDA approved for adults with schizophrenia.

More women than men said they needed mental health services in the past 2 years (50% vs 35%), but only half of them obtained an appointment for care, the 2022 Kaiser Family Foundation Women’s Health Survey showed.

Cerevel Therapeutics’ investigational drug emraclidine — a positive allosteric modulator designed to selectively target the M4 muscarinic receptor subtype — was cleared of blood pressure risks in people with schizophrenia during an 8-week study designed in line with FDA guidance.